These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 38480689)

  • 1. Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasion.
    Planas D; Staropoli I; Michel V; Lemoine F; Donati F; Prot M; Porrot F; Guivel-Benhassine F; Jeyarajah B; Brisebarre A; Dehan O; Avon L; Bolland WH; Hubert M; Buchrieser J; Vanhoucke T; Rosenbaum P; Veyer D; Péré H; Lina B; Trouillet-Assant S; Hocqueloux L; Prazuck T; Simon-Loriere E; Schwartz O
    Nat Commun; 2024 Mar; 15(1):2254. PubMed ID: 38480689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasion.
    Planas D; Staropoli I; Michel V; Lemoine F; Donati F; Prot M; Porrot F; Guivel-Benhassine F; Jeyarajah B; Brisebarre A; Dehan O; Avon L; Boland WH; Hubert M; Buchrieser J; Vanhoucke T; Rosenbaum P; Veyer D; Péré H; Lina B; Trouillet-Assant S; ; Hocqueloux L; Prazuck T; Simon-Loriere E; Schwartz O
    bioRxiv; 2024 Feb; ():. PubMed ID: 38045308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct patterns of SARS-CoV-2 BA.2.87.1 and JN.1 variants in immune evasion, antigenicity, and cell-cell fusion.
    Li P; Liu Y; Faraone JN; Hsu CC; Chamblee M; Zheng Y-M; Carlin C; Bednash JS; Horowitz JC; Mallampalli RK; Saif LJ; Oltz EM; Jones D; Li J; Gumina RJ; Liu S-L
    mBio; 2024 May; 15(5):e0075124. PubMed ID: 38591890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Temperature-dependent Spike-ACE2 interaction of Omicron subvariants is associated with viral transmission.
    Benlarbi M; Ding S; Bélanger É; Tauzin A; Poujol R; Medjahed H; El Ferri O; Bo Y; Bourassa C; Hussin J; Fafard J; Pazgier M; Levade I; Abrams C; Côté M; Finzi A
    mBio; 2024 Aug; 15(8):e0090724. PubMed ID: 38953636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Less neutralization evasion of SARS-CoV-2 BA.2.86 than XBB sublineages and CH.1.1.
    Hu Y; Zou J; Kurhade C; Deng X; Chang HC; Kim DK; Shi PY; Ren P; Xie X
    Emerg Microbes Infect; 2023 Dec; 12(2):2271089. PubMed ID: 37824708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutralization of SARS-CoV-2 Omicron XBB.1.5 and JN.1 variants after COVID-19 booster-vaccination and infection.
    Springer DN; Camp JV; Aberle SW; Deutsch J; Lammel O; Weseslindtner L; Stiasny K; Aberle JH
    J Med Virol; 2024 Jul; 96(7):e29801. PubMed ID: 38988204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cross-neutralizing antibody against emerging Omicron subvariants of SARS-CoV-2 in infection-naïve individuals with homologous BNT162b2 or BNT162b2(WT + BA.4/5) bivalent booster vaccination.
    Cheng SMS; Mok CKP; Li JKC; Chan KKP; Luk KS; Lee BHW; Gu H; Chan KCK; Tsang LCH; Yiu KYS; Ling KKC; Tang YS; Luk LLH; Yu JKM; Pekosz A; Webby RJ; Cowling BJ; Hui DSC; Peiris M
    Virol J; 2024 Mar; 21(1):70. PubMed ID: 38515117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neutralizing antibody response to XBB.1.5, BA.2.86, FL.1.5.1, and JN.1 six months after the BNT162b2 bivalent booster.
    Favresse J; Gillot C; Cabo J; David C; Dogné JM; Douxfils J
    Int J Infect Dis; 2024 Jun; 143():107028. PubMed ID: 38583825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants.
    Wang Q; Iketani S; Li Z; Liu L; Guo Y; Huang Y; Bowen AD; Liu M; Wang M; Yu J; Valdez R; Lauring AS; Sheng Z; Wang HH; Gordon A; Liu L; Ho DD
    Cell; 2023 Jan; 186(2):279-286.e8. PubMed ID: 36580913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinct Patterns of SARS-CoV-2 BA.2.87.1 and JN.1 Variants in Immune Evasion, Antigenicity and Cell-Cell Fusion.
    Li P; Liu Y; Faraone J; Hsu CC; Chamblee M; Zheng YM; Carlin C; Bednash JS; Horowitz JC; Mallampalli RK; Saif LJ; Oltz EM; Jones D; Li J; Gumina RJ; Liu SL
    bioRxiv; 2024 Mar; ():. PubMed ID: 38559216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune evasion and membrane fusion of SARS-CoV-2 XBB subvariants EG.5.1 and XBB.2.3.
    Faraone JN; Qu P; Goodarzi N; Zheng YM; Carlin C; Saif LJ; Oltz EM; Xu K; Jones D; Gumina RJ; Liu SL
    Emerg Microbes Infect; 2023 Dec; 12(2):2270069. PubMed ID: 37819267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune Evasion of SARS-CoV-2 Omicron Subvariants XBB.1.5, XBB.1.16 and EG.5.1 in a Cohort of Older Adults after ChAdOx1-S Vaccination and BA.4/5 Bivalent Booster.
    Machado RRG; Candido ÉD; Aguiar AS; Chalup VN; Sanches PR; Dorlass EG; Amgarten DE; Pinho JRR; Durigon EL; Oliveira DBL
    Vaccines (Basel); 2024 Jan; 12(2):. PubMed ID: 38400128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SARS-CoV-2 Omicron XBB subvariants exhibit enhanced fusogenicity and substantial immune evasion in elderly population, but high sensitivity to pan-coronavirus fusion inhibitors.
    Xia S; Jiao F; Wang L; Yu X; Lu T; Fu Y; Huang Z; Li X; Huang J; Wang Q; Man Q; Xiong L; Jiang S; Lu L
    J Med Virol; 2023 Mar; 95(3):e28641. PubMed ID: 36890632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ultrapotent class I neutralizing antibodies post Omicron breakthrough infection overcome broad SARS-CoV-2 escape variants.
    Luo M; Zhou R; Tang B; Liu H; Chen B; Liu N; Mo Y; Zhang P; Lee YL; Ip JD; Wing-Ho Chu A; Chan WM; Man HO; Chen Y; To KK; Yuen KY; Dang S; Chen Z
    EBioMedicine; 2024 Oct; 108():105354. PubMed ID: 39341153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progressive loss of conserved spike protein neutralizing antibody sites in Omicron sublineages is balanced by preserved T cell immunity.
    Muik A; Lui BG; Quandt J; Diao H; Fu Y; Bacher M; Gordon J; Toker A; Grosser J; Ozhelvaci O; Grikscheit K; Hoehl S; Kohmer N; Lustig Y; Regev-Yochay G; Ciesek S; Beguir K; Poran A; Vogler I; Türeci Ö; Sahin U
    Cell Rep; 2023 Aug; 42(8):112888. PubMed ID: 37527039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutralization of SARS-CoV-2 Omicron subvariant BA.2.87.1.
    Lasrado N; Rössler A; Rowe M; Collier AY; Barouch DH
    Vaccine; 2024 Apr; 42(9):2117-2121. PubMed ID: 38458874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SARS-CoV-2 BA.1 and BA.2 breakthrough infections boost antibody responses to early Omicron subvariants but not BQ.1.1 or XBB.1.5.
    Abbad A; Yellin T; Singh G; Fried M; Raskin A; Tcheou J; Monahan B; Gleason C; ; Simon V; Carreño JM; Krammer F
    Cell Rep Med; 2024 Mar; 5(3):101474. PubMed ID: 38508136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutralization against Omicron subvariants after BA.5/BF.7 breakthrough infection weakened as virus evolution and aging despite repeated prototype-based vaccination
    Wang H; Xue Q; Zhang H; Yuan G; Wang X; Sheng K; Li C; Cai J; Sun Y; Zhao J; Lu J; Fang S; Yang Y; Zhang Y; Huang Y; Wang J; Xu JH; Jiang MX; Wang X; Shen L; Liu Y; Liu Q; Zhang Q; Wang S; Wang P; Qiu C; Ai J; Zhang W
    Emerg Microbes Infect; 2023 Dec; 12(2):2249121. PubMed ID: 37668156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutralization escape by SARS-CoV-2 Omicron subvariant BA.2.86.
    Lasrado N; Collier AY; Hachmann NP; Miller J; Rowe M; Schonberg ED; Rodrigues SL; LaPiana A; Patio RC; Anand T; Fisher J; Mazurek CR; Guan R; Wagh K; Theiler J; Korber BT; Barouch DH
    Vaccine; 2023 Nov; 41(47):6904-6909. PubMed ID: 37872011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune escape of BA.2.86 is comparable to XBB subvariants from the plasma of BA.5- and BA.5-XBB-convalescent subpopulations.
    Yang X; Wang Y; Liang Z; Cui T; Chen D; Li G; Xu H; Liu S; Zhong N; Huang W; Wang Z
    J Med Virol; 2024 Jan; 96(1):e29417. PubMed ID: 38258345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.